Announced Sat, 30 May · 19:26 IST

Results for the financial year ended on March 31, 2026

Revenue DeclinePat NegativeEbitda Margin CompressionResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.4%1-day move
₹478.00
prior close
₹526.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0-1.7-3.3-1.9+6.4+7.5+7.3+6.5+5.1+4.8+28.7+28.5
Up moveDown movePending
AI summary

Coral Laboratories Ltd reported audited standalone results for FY2026 ending March 31, 2026. Revenue from operations fell to Rs 8,589.97 lakhs from Rs 11,500.53 lakhs in FY2025, representing a 25.3% decline. Profit for the period dropped to Rs 1,638.13 lakhs from Rs 2,415.56 lakhs, a 32.2% decline year-over-year. EPS declined from Rs 67.61 to Rs 45.85. Operating margin compressed from 28.9% to 26.5%. The Board recommended a final dividend of 20% (Rs 2 per share). The statutory auditor issued an unmodified opinion. The company appointed new internal and cost auditors for FY2027. Capital expenditure increased significantly to Rs 2,353.18 lakhs (vs Rs 46.35 lakhs prior year), indicating major investments in PP&E.

Likely market impact

The stock may face pressure due to significant revenue and profit decline. However, maintained dividend, strong cash flow from operations (Rs 1,561.54 lakhs), and heavy capex investments suggest the company is investing for recovery despite near-term headwinds.